HIV VACCINE TRIALS NETWORK
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Safety and Immunogenicity of mRNAs Encoding HIV Immunogens (eOD-GT8 60mer, Core-g28v2 60mer, N332-GT5 gp151) in Adult Participants Without HIV and in Overall Good Health in South Africa (HVTN 317)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 96
- Registration Number
- NCT06694753
- Locations
- 🇿🇦
Setshaba Research Centre CRS, Soshanguve, Gauteng, South Africa
🇿🇦Soweto HVTN CRS, Soweto, Gauteng, South Africa
🇿🇦Chatsworth CRS, Chatsworth, Kwa Zulu Natal, South Africa
Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected
- Conditions
- HIV Infections
- Interventions
- Biological: Placebo and DiluentBiological: 3M-052-AF
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 22
- Registration Number
- NCT06613789
- Locations
- 🇿🇦
Soweto HVTN CRS, Soweto, Gauteng, South Africa
Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants
- Conditions
- HIV Infections
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 77
- Registration Number
- NCT05959707
- Locations
- 🇿🇦
Groote Schuur HIV CRS, Cape Town, Western Cape, South Africa
🇿🇦Emavundleni CRS, Klipfontein, Western Cape, South Africa
🇿🇦CAPRISA eThekwini CRS, Durban, South Africa
Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa
- Conditions
- TuberculosisHIV I Infection
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 276
- Registration Number
- NCT05947890
- Locations
- 🇿🇦
Johannesburg - CHRU, Westdene, Gauteng,, South Africa
🇿🇦Soweto - Gauteng, Johannesburg, Gauteng, South Africa
🇿🇦Durban - Botha's Hill CRS, Durban, Kwa Zulu Natal, South Africa
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
- Conditions
- HIV Infections
- Interventions
- Biological: PlaceboBiological: CH505TF gp120
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- HIV Vaccine Trials Network
- Target Recruit Count
- 34
- Registration Number
- NCT05182125
- Locations
- 🇿🇦
Emavundleni CRS, Cape Town, South Africa
🇿🇦CAPRISA eThekwini CRS, Durban, South Africa
🇿🇦Isipingo CRS, Isipingo, South Africa
- Prev
- 1
- 2
- 3
- Next
News
HIV Vaccine Breakthrough: New Candidate Successfully Generates Broadly Neutralizing Antibodies
NIAID-supported clinical trial demonstrates that an HIV vaccine candidate can elicit broadly neutralizing antibodies (bNAbs) targeting the membrane proximal external region (MPER) of HIV, a crucial step toward developing an effective preventive vaccine.